Seguir
Josée Zijlstra
Josée Zijlstra
Associate Professor of Hematology, VU University Medical Center, Amsterdam
Dirección de correo verificada de vumc.nl
Título
Citado por
Citado por
Año
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R Boellaard, R Delgado-Bolton, WJG Oyen, F Giammarile, K Tatsch, ...
European journal of nuclear medicine and molecular imaging 42, 328-354, 2015
28622015
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ...
Journal of clinical oncology 25 (5), 571-578, 2007
16812007
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ...
European journal of nuclear medicine and molecular imaging 37, 181-200, 2010
15852010
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ...
The Lancet 379 (9828), 1791-1799, 2012
7562012
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
6342012
Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma
M Schaapveld, BMP Aleman, AM van Eggermond, CPM Janus, ADG Krol, ...
New England Journal of Medicine 373 (26), 2499-2511, 2015
6092015
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
R Boellaard, WJG Oyen, CJ Hoekstra, OS Hoekstra, EP Visser, ...
European journal of nuclear medicine and molecular imaging 35, 2320-2333, 2008
4512008
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
ML De Bruin, J Sparidans, MB van't Veer, EM Noordijk, MWJ Louwman, ...
Journal of Clinical oncology 27 (26), 4239-4246, 2009
4322009
Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
B Von Tresckow, A Plütschow, M Fuchs, B Klimm, J Markova, A Lohri, ...
J Clin Oncol 30 (9), 907-913, 2012
3892012
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin …
P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ...
The Lancet 390 (10114), 2790-2802, 2017
3712017
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced …
C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, ...
Blood, The Journal of the American Society of Hematology 112 (10), 3989-3994, 2008
2802008
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review
JM Zijlstra, G Lindauer-van der Werf, OS Hoekstra, L Hooft, PC Huijgens
Haematologica 91 (4), 522-529, 2006
2742006
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ...
The Lancet Haematology 7 (7), e511-e522, 2020
2732020
Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review
JC Regelink, MC Minnema, E Terpos, MH Kamphuis, PG Raijmakers, ...
British journal of haematology 162 (1), 50-61, 2013
2582013
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non …
K Behringer, H Goergen, F Hitz, JM Zijlstra, R Greil, J Markova, S Sasse, ...
The Lancet 385 (9976), 1418-1427, 2015
2212015
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
E Vellenga, WLJ van Putten, MB van't Veer, JM Zijlstra, WE Fibbe, ...
Blood, The Journal of the American Society of Hematology 111 (2), 537-543, 2008
2182008
Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German …
M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri, R Greil, S Sasse, ...
Journal of clinical oncology 37 (31), 2835-2845, 2019
2022019
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
LR Perk, OJ Visser, M Stigter-van Walsum, MJWD Vosjan, GWM Visser, ...
European journal of nuclear medicine and molecular imaging 33, 1337-1345, 2006
1992006
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, ...
The Lancet Oncology 20 (2), 216-228, 2019
1922019
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?
YWS Jauw, CW Menke-van der Houven van Oordt, OS Hoekstra, ...
Frontiers in pharmacology 7, 131, 2016
1662016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20